Company news

ImmuneOnco completes the transfer cooperation of a project

2019-11-8 0:00:00Click:163

 On November 7, 2019, ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. (Abbreviation: ImmuneOnco) completed the transfer cooperation of a project. It is agreed that the transferee of the project shall obtain the rights and interests of the development, registration, production and sales of the bispecific antibody project in the domestic market of China, and shall receive the down payment, follow-up milestone payment and post sales share for this purpose. The transferee of the project will provide the domestic preclinical and clinical research data to ImmuneOnco for registration and application in the market outside China. Both sides agreed to give full play to their own advantages, strengthen close cooperation and continuously develop new immunotherapy drugs with independent intellectual property rights for cancer patients in China. The first contract payment has been received by the time of publication.

 Wenzhi Tian, the founder and chairman of ImmuneOnco, said: "ImmuneOnco has an efficient research and development technology platform for anti-tumor drugs with new immune regulatory targets, and has unique strength in drug design and screening. We have rich and distinctive prospective project pipelines, and several bispecific protein drugs have shown good development prospects, and will continue to vigorously promote these projects in the future. I hope that in the near future, one new drug after another will be born in China. We will aim at the tumor microenvironment, continue to work in the field of anti-tumor immunotherapy, accelerate the pace of research and development, develop high-quality biological drugs that are affordable to the people, and contribute to the development of China's biopharmaceutical industry. " "Here, I sincerely thank all members of the company for their outstanding performance. It is their hard work that makes the company achieve one milestone after another.".

 About ImmuneOnco

 ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. was founded in June 2015 and registered in Shanghai Zhangjiang High-tech Park. The company is mainly committed to the development of immunotherapy products for cancer, including bispecific antibodies, new recombinant proteins, and CAR-NK cell therapy. IMM01, the first product of the company, is in phase I clinical trial study, and IMM0306, the second product, is in clinical acceptance.